Romy Zwittink is a researcher for the Department of Medical Microbiology at Leiden University Medical Centre and will be speaking at the NCOH Annual Scientific Meeting on 30 May 2018 on the subject of Clostridium difficile and the intestinal microbiome. We asked her three preliminary questions.
What question are you trying to answer with your research?
We are researching the relationship between the composition of the intestinal microbiota and the presence of Clostridium difficile bacteria.
Why is this important?
Clostridium difficile makes up part of the intestinal microbiota in approximately four per cent of people. When this balance is disrupted, due to the use of antibiotics, for example, Clostridium difficile can become dominant, produce toxins and cause intestinal infections. If the standard treatment does not work, and the infection recurs, transplantation of faecal microbiota may offer a solution. This treatment ensures that the levels of gut microbiota return to normal and the production of toxins by Clostridium difficile is suppressed.
Clostridium difficile can be present in the intestinal microbiota without causing disease. These ‘asymptomatic carriers’ probably play a role in spreading the bacteria in the environment and to other people, in hospitals and nursing homes, for example. We currently have too little insight into the factors influenced by asymptomatic carriers. The composition and function of the intestinal microbiota could possibly play a role.
What do you ultimately want to achieve?
Our ultimate goal is to reduce the number of Clostridium difficile infections and in doing so reduce the related morbidity and mortality. Once we know the type of composition of the gut microbiota, or which specific microorganisms suppress the colonisation or growth of Clostridium difficile, we can respond accordingly. For example, we can then select the best donor for faecal transplantation, or develop this principle further to create a supplement containing specific microorganisms to either cure or prevent Clostridium difficile infections.
It’s time for an update! You and all NCOH scientists are invited to join the NCOH Science Café on 29 October 2019 to get up to speed with the latest developments, meet fellow NCOH colleagues, and establish new collaborations. Feel free to inform your fellow researchers and PhD students about the Science Café, they will...
Researchers from the National Institute for Public Health and the Environment, Utrecht University, University Medical Center Utrecht, the Animal Health Service and Wageningen Bioveterinary Research, all members of the ESBLAT consortium, have previously shown that ESBL antimicrobial resistance is common in humans, livestock and companion animals, food of animal origin and the environment. However, ESBL...
The Netherlands Centre for One Health (NCOH) was allocated a budget of two million euro Public-Private Partnership (PPP) Allowance to organise and realise their first PPP call. This call involves strategic partnerships under the Knowledge and Innovation Agenda of Top Sector Life Sciences & Health (LSH): One Health call.
The number of bacteria that are resistant to antibiotics is increasing globally. In the Netherlands this number remains fairly stable and is lower than in many other countries. Nevertheless, there is still cause for concern and caution. This is evident from the annual report NethMap/MARAN 2019 in which various organisations jointly present data on antibiotic...